Bayer Files for Indian Approval of Finerenone (Kerendia) for Heart Failure Indication
AI-Generated Summary
Pharmaceutical giant Bayer has initiated the regulatory process in India to gain approval for finerenone (Kerendia) to treat heart failure patients with LVEF of 40 and above. This move follows successful clinical trials and aims to address the rising burden of heart disease in India. Finerenone is already approved in India for chronic kidney disease, and Bayer anticipates approval for this new heart failure indication by year-end.
In a nutshell
This development highlights Bayer's strategic expansion into a critical therapeutic area in a growing market. The successful trials and anticipated approval for finerenone underscore the ongoing efforts in drug development to address widespread cardiovascular diseases, offering a new therapeutic option for patients.
Source: The Economic Times
